Journal ArticleOPEN ACCESS

Setting the pick: Can PI3K inhibitors circumvent CDK4/6 inhibitor resistance?

Clinical Cancer Research (2021) 27(2) 371-373
DOI: 10.1158/1078-0432.CCR-20-3624
23Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.

Cite

CITATION STYLE

APA

Clark, A. S., Makhlin, I., & DeMichele, A. (2021). Setting the pick: Can PI3K inhibitors circumvent CDK4/6 inhibitor resistance? Clinical Cancer Research, 27(2), 371–373. https://doi.org/10.1158/1078-0432.CCR-20-3624

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free